
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics is a promising biotech company with a strong pipeline of drug candidates using their POZ platform technology, particularly in the treatment of Parkinson's disease and Tardive Dyskinesia. The company's upcoming data for SER-252 will be a significant catalyst for their success, with potential for partnerships and revenue from their Grant revenue segment. While there are risks associated with biotech companies, analysts have a positive outlook for Serina Therapeutics, with a projected price target of $40.
Bears say
Serina Therapeutics is facing significant risks and challenges as a clinical-stage biotechnology company, which may negatively impact its stock. These include the potential for unexpected safety signals in upcoming clinical trials for its main product candidate, SER-252, as well as competition from other drug developers and ongoing research into disease-modifying treatments for neurological diseases such as Parkinson's. In addition, the company's focus on its POZ platform and its potential partnerships may divert attention and resources away from its key internal programs. Furthermore, there is a risk of potential commercial challenges, such as pricing and reimbursement coverage, if the company's products are approved for market.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares